Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants
收藏DataCite Commons2024-11-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002925/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme of Immunisation vaccines regimen to healthy infants aged between and including 2 and 7 months, living in a tuberculosis endemic region.
提供机构：
Vivli
创建时间：
2018-10-27
